* EPS down by c9% yoy to BDT 8.57 in Q2 CY22. * Sales down by c9% yoy driven by volume sales decline resulting from inflationary pressure and price hike of products. * Gross margin down by 773 bps yoy due to abnormally high gross margin in Q2 CY22 and increased raw material costs driven by BDT depreciation. * Effective tax rate rose 264 bps to c23% as it paid a similar level of taxes on comparatively lower sales in Q2 CY23 compared to that in Q2 CY22.
* The cumulative profits of Multinational Companies (MNCs), excluding BERGERPBL, increased by c5% yoy in Jan-Mar 2023. * Consumer staple companies experienced continued growth, performing well during the quarter: * MARICO’s profit grew c. 25% this quarter because of profitability improvement driven by lower copra price and opex management * RECKITTBEN resumed topline growth and generated strong earnings growth by trimming operating expenses * All construction companies ...
* Earnings rose c17% yoy in Q1 CY23. Earnings stood at BDT 201 mn (BDT 16.71) in Q1 CY23 against BDT 173 mn (BDT 14.33) in Q1 CY22. This rise was mainly driven by substantial net finance income growth and 651 bps effective tax rate fall. * Revenue fell c11% yoy in Q1 CY23. Revenue stood at BDT 1,085 mn in Q1 CY23 against BDT 1,215 mn in Q1 CY22. The decline in Q1 CY23 revenue was driven by a c13% yoy decline in health food drink sales which stood at BDT 915 mn while glucose powder sales...
* Earnings rose c17% yoy in Q1 CY23. Earnings stood at BDT 201 mn (BDT 16.71) in Q1 CY23 against BDT 173 mn (BDT 14.33) in Q1 CY22. This rise was mainly driven by substantial net finance income growth and 651 bps effective tax rate fall. * Revenue fell c11% yoy in Q1 CY23. Revenue stood at BDT 1,085 mn in Q1 CY23 against BDT 1,215 mn in Q1 CY22. The decline in Q1 CY23 revenue was driven by a c13% yoy decline in health food drink sales which stood at BDT 915 mn while glucose powder sales...
* c35% yoy NPAT growth in Q4 CY22; CY22 profit rose by c39% yoy. NPAT increased by c35% to BDT 190mn in Q4 CY'22 from BDT 141mn in Q4 CY'21. Annual EPS stood at BDT 60.64 in CY’22 against BDT 43.80 in CY’21. This earnings growth is due to the one off gain of BDT 400 mn from the reassessment of past liabilities and obligations. Without this gain, CY22 earnings would be BDT 420 mn, implying a c20% yoy decline. The decline can be attributed to higher raw material and packing costs driven...
Glaxow BD reported 3Q CY 20 NPAT of BDT 140.7mn (EPS: BDT11.68), implying c45% yoy de-growth against NPAT of BDT254.7mn (EPS: BDT21.14) in 3Q CY 19. Revenue de-growth of c10% yoy and gross margin contraction of 1,949bps yoy could not be offset by 472bps yoy lower operating expense as a percentage of sales. In the first nine months of CY 20, Glaxow BD’s NPAT stood at BDT458.4mn (EPS: BDT38.05), down by 12.3% yoy against BDT522.7mn (EPS: BDT43.39) in the same period of CY 19. As the earnings gr...
Glaxow BD reported 2Q CY 20 NPAT of BDT137mn (EPS: BDT11.40), implying c2% yoy growth against NPAT of BDT135mn (EPS: BDT11.19) in 2Q CY 19. However, if we exclude the effect of loss of discontinuing operations and lower tax, profit before tax shows de-growth of 5.2% yoy. Revenue de-growth of c13% yoy and gross margin contraction of 439bps yoy could not be offset by 493bps yoy lower operating expense as a percentage of sales and c38% yoy higher net finance income. In the first six months of CY...
Glaxow BD to become Unilever Consumer Care after the transfer of 9.88mn shares. Unilever announced the successful completion of acquiring 81.98% shares of GlaxoSmithKline Bangladesh on 30 June, 2020. Unilever Overseas Holdings BV, a concern of Unilever, took over 9,875,144 shares from Setfirst, a concern of GSK Group, on the block market at Dhaka Stock Exchange on 28th June, 2020. The remaining 18% stake is owned by the general and institutional investors. After this transfer to the Unilever ...
A director at Glaxo Wellcome Bangladesh sold 784 shares at 0.000BDT and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
The long ‘Holiday’ hits the season of the largest retail sales. Bangladesh identified the first Covid-19 patient on 8 March and has reported 25,121 confirmed cases, 370 deaths, and 4,993 recoveries till 19th May 2020. Bangladesh is set to experience a 66-day long ‘holiday’ till 30th May, comprising of 38 days of general holiday (i.e. lockdowns), 20 weekends, and 8 public holidays. The supply-side experienced distribution challenges from the law enforcement agency during the first two wee...
Glaxow BD reported 1Q CY 20 NPAT of BDT180.4mn (EPS: BDT14.97),implying c35% growth against NPAT of BDT133.2mn (EPS: BDT11.06) in 1Q CY 19. However, if we exclude the effect of loss of discontinuing operations and lower tax, profit before tax shows mere c3% yoy growth. Revenue continued to slide, falling by 6% yoy.Glaxow BD’s revenue decreased to BDT1,154.4mn in 1Q CY 20 from BDT 1,229.6mn in 1Q CY 19 as Glaxow BD is struggling to generate volume growth for quite some time mainly due to lower....
Earnings grew by 21% amid fall in top-line and rise in opex: GLAXOW BD reported earnings of BDT 135mn (EPS BDT 11.2) in Q2 19 (Apr-Jun), rising by 207% yoy in spite of fall in top-line by 5% yoy and rise in opex/sales by 382bps. Excluding the effect of discontinued operation (Pharma segment), profit from continuing operation stood at BDT154mn, rising by BDT c21% yoy from BDT128mn in the same period, last year. Gross profit margin (GPM) expansion of c768bps yoy has mainly driven this growth. Net ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.